A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
Protocol No: GS-US-223-1017, IRB Protocol# 20191679
Sponsor: Gilead Sciences, Inc.
Investigator: Kianoosh Kaveh, DO
Purpose of this Study
You have been asked to participate in this study because you have T2DM and moderate to advanced DKD. Your kidneys are located in the middle of your back under your rib cage. The main job of your kidneys is to clean your blood. When your kidneys are damaged, they can’t clean your blood causing waste and fluids to build up in your blood rather than leave your body. If damage of your kidneys continues it can lead to other health problems and your kidneys could fail. Patients with kidney failure need either dialysis or a kidney transplant.
The purpose of this study is to see if SEL can slow or stop the progression of kidney damage and delay time to kidney failure in patients with DKD.
Will you be paid to be part of this study?
You will be paid $60 per visit. You will receive a study stipend, via check, once every quarter for study visits completed during that time.
Questions or concerns?
Your answers on the questionnaire are not set in stone. If you are unsure about an entry, simply make a note in the Additional Questions or Concerns field at the bottom of the form.